<DOC>
	<DOCNO>NCT01741948</DOCNO>
	<brief_summary>There report medical literature demonstrate link development provoke vestibulodynia ( PVD ) , sexual pain disorder , hormonal contraceptive ( HC ) use . The purpose pilot study assess prevalence HCs induce PVD among HC naïve population , evaluate component HCs associate high risk development PVD , evaluate clinical genetic factor predispose patient HCs induce PVD . Assessments make patient questionnaire , physical examination , blood test . Microarray techniques employ characterize , global level , gene expression profile woman develop PVD comparison develop PVD . Patients follow year . Results use develop large clinical trial .</brief_summary>
	<brief_title>Hormonal Contraceptive Use Risk Provoked Vestibulodynia</brief_title>
	<detailed_description>Background : Provoked vestibulodynia ( PVD ) , previously call vulvar vestibulitis syndrome , clinically define chronic , unexplained , vulvar pain discomfort , confine vulvar vestibule , response contact pressure . As result , woman PVD experience pain sexual intercourse , many patient also pain response non-sexual activity . The actual prevalence PVD unknown , current evidence indicate lifetime cumulative incidence vulvodynia approach 15 % . Currently , PVD think lead cause dyspareunia premenopausal woman . Once woman PVD develop syndrome , symptom may last year ; result , PVD profound effect woman 's sexuality psychological well-being . The diagnosis PVD usually make assess presence modify Friedrich 's criterion . These criterion consist 1 ) history vulvar pain , dyspareunia pain tampon insertion , 2 ) tenderness vestibule touch cotton-tip applicator , 3 ) identifiable cause pain ( vaginitis , dermatitis etc. ) . The etiology condition remain unknown . Proposed cause include chronic inflammation , peripheral neuropathy , genetic , immunologic and\or hormonal factor , infection , psychological disorder , sexual dysfunction , disturbance central nervous system . Several study demonstrate increase risk develop PVD secondary hormonal contraceptive ( HC ) usage . The relative risk develop PVD seem rise increase duration HCs use ( least 2-4 year use ) , first use HCs young age ( &lt; 16 year ) , hormonal composition HCs , specifically progestogenic , estrogenic , androgenic potency pill . Several mechanisms action suggest HCs induce PVD : - Alteration vestibular hormonal receptor . - Alterations morphological pattern vestibular mucosa ( 13 ) . - Decreased pain threshold . - Alteration serum free hormone level . Objectives/Purpose Study : 1 . To assess actual prevalence HCs induce PVD prospective study . 2 . To evaluate component contain HCs ( oral contraceptive , transdermal patch , vaginal ring ) associate high risk HCs induce PVD , specifically ; dose ethinyl estradiol ( 15 , 20 30 mcg ) progesterone component . 3 . To evaluate factor predispose patient HCs induce PVD . We analyze clinical ( age , age menarche , length use , body mass index etc . ) , hormonal ( E2 , testosterone etc . ) alter gene expression factor . The propose study preliminary investigation aim estimate rate HCs induce PVD . The data study enable determination number patient need obtain statistical significance future , large study regard patient ' risk factor develop PVD HCs formulation . For pilot study investigator evaluate 200 patient follow total 1 year HC initiation . Since novel study investigate , available statistic medical literature , investigator anticipate 200 patient provide enough data regard incidence PVD development secondary HCs use . Definitions measure use diagnose HC induce PVD : 1 . New onset vulvar pain suggestive PVD , i.e . symptom pain vaginal penetration ( insertional dyspareunia and/or pain tampon insertion ) , follow initiation HCs . 2 . On exam , tenderness localize within vestibule touch cotton-tip applicator . The exam perform defined point labia minora , labia majora vestibule 5 define point ( 1,5,6,7,11 ) , patient report pain verbally rating scale 0 10 point . 3 . No identifiable cause pain , vulvovaginal candidiasis , desquamative inflammatory vaginitis ( DIV ) , herpes , dermatitis vulvar dystrophy . Time frame completion : The investigator anticipate one year patient ' enrollment another year follow . Data analysis microarray analyse do third year . Data available within 3 year study initiation .</detailed_description>
	<mesh_term>Vulvodynia</mesh_term>
	<mesh_term>Vulvar Vestibulitis</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>200 non pregnant woman 1835 naïve HCs hormonal medication . Patients able provide Informed Consent complete questionnaire . Patient intend use HCs least one year . On exam initiation HCs , patient primary PVD , pelvic floor hypertonicity , vaginismus congenital abnormality . Patient available follow appointment . Patient willing undergo gynecologic examination , dyspareunia develops . Patients endocrine disturbance ( include PCOS ) , liver disease eat disorder . Patients suffer Hypertension , Migraine aura clot disturbance . Patients experience pain intercourse tampon insertion . Patients contraindication HCs use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Provoked vestibulodynia</keyword>
	<keyword>Hormonal contraceptive</keyword>
</DOC>